Premaitha Health PLC Premaitha announces two laboratory hub contracts (5206K)
July 10 2017 - 1:00AM
UK Regulatory
TIDMNIPT
RNS Number : 5206K
Premaitha Health PLC
10 July 2017
Premaitha Health plc
("Premaitha" or the "Company" or the "Group")
Premaitha announces two laboratory hub contracts in South East
Asia
Manchester, UK - 10 July 2017: Premaitha Health plc (AIM: NIPT),
a leading international molecular diagnostics group focused on
non-invasive prenatal testing ("NIPT"), announces that it has
signed contracts with two significant laboratories in South East
Asia through its Taiwanese subsidiary, Yourgene Bioscience
("Yourgene").
The agreements have been signed with two partners for
laboratories which are in different countries in South East Asia
and will act be established as regional hubs for NIPT. Both
partners are already established providers of NIPT in their
domestic markets with ambitions to further expand across the
region. One partner is also amongst the largest listed genomic
testing companies in Asia and will market the test under its own
brand.
Dr Stephen Little, CEO, commented: "South East Asia is a very
important region for Premaitha as the NIPT market is
well-established and growing apace. These newly secured market
leading partners will increase Premaitha's presence in the region,
whilst further expanding our routes to market.
"We continue to work with our partners globally to increase
awareness of the benefits of NIPT as we seek to further strengthen
our footprint."
For more information, please contact:
Premaitha Health plc Tel: +44 (0)
161 667 6865
Dr Stephen Little, Chief Executive
Office
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (Nomad) Tel: +44 (0)
20 7213 0880
Liam Murray / James Caithie
finnCap (Broker) Tel: +44 (0)
20 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Tony Quirke (Corporate Broking)
Vigo Communications Tel: +44 (0)
20 7830 9701
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of fetal DNA - and estimates the risk of a fetus
being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUGUMWMUPMPUB
(END) Dow Jones Newswires
July 10, 2017 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024